State Street’s Viridian Therapeutics VRDN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $113M | Buy |
6,124,976
+1,452,091
| +31% | +$23.4M | ﹤0.01% | 1413 |
|
|
2026
Q1 | $91.4M | Buy |
4,672,885
+1,206,325
| +35% | +$35.8M | ﹤0.01% | 1423 |
|
|
2025
Q4 | $108M | Buy |
3,466,560
+912,394
| +36% | +$25M | ﹤0.01% | 1311 |
|
|
2025
Q3 | $55.1M | Buy |
2,554,166
+740
| +0% | +$13.3K | ﹤0.01% | 1680 |
|
|
2025
Q2 | $35.7M | Sell |
2,553,426
-312,074
| -11% | -$4.24M | ﹤0.01% | 1859 |
|
|
2025
Q1 | $38.6M | Sell |
2,865,500
-657,066
| -19% | -$11.2M | ﹤0.01% | 1776 |
|
|
2024
Q4 | $67.5M | Buy |
3,522,566
+1,142,792
| +48% | +$24.8M | ﹤0.01% | 1565 |
|
|
2024
Q3 | $54.1M | Sell |
2,379,774
-392,605
| -14% | -$6.42M | ﹤0.01% | 1669 |
|
|
2024
Q2 | $36.1M | Sell |
2,772,379
-1,716,236
| -38% | -$23.8M | ﹤0.01% | 1827 |
|
|
2024
Q1 | $78.6M | Buy |
4,488,615
+1,780,232
| +66% | +$34.5M | ﹤0.01% | 1459 |
|
|
2023
Q4 | $59M | Sell |
2,708,383
-233,307
| -8% | -$3.68M | ﹤0.01% | 1619 |
|
|
2023
Q3 | $45.1M | Buy |
2,941,690
+23,321
| +0.8% | +$445K | ﹤0.01% | 1691 |
|
|
2023
Q2 | $69.4M | Buy |
2,918,369
+516,557
| +22% | +$13.2M | ﹤0.01% | 1460 |
|
|
2023
Q1 | $61.1M | Buy |
2,401,812
+538,622
| +29% | +$17.3M | ﹤0.01% | 1513 |
|
|
2022
Q4 | $54.4M | Buy |
1,863,190
+684,641
| +58% | +$15.8M | ﹤0.01% | 1572 |
|
|
2022
Q3 | $24.2M | Buy |
1,178,549
+723,484
| +159% | +$13M | ﹤0.01% | 2083 |
|
|
2022
Q2 | $5.26M | Buy |
455,065
+389,065
| +589% | +$5.23M | ﹤0.01% | 3078 |
|
|
2022
Q1 | $1.22M | Buy |
66,000
+31,959
| +94% | +$614K | ﹤0.01% | 3744 |
|
|
2021
Q4 | $673K | Buy |
34,041
+10,200
| +43% | +$190K | ﹤0.01% | 3911 |
|
|
2021
Q3 | $392K | Buy |
23,841
+12,800
| +116% | +$188K | ﹤0.01% | 4074 |
|
|
2021
Q2 | $202K | Buy |
+11,041
| New | +$189K | ﹤0.01% | 4211 |
|
|
2020
Q4 | – | Sell |
-827
| Closed | -$10K | – | 3909 |
|
|
2020
Q3 | $10K | Hold |
827
| – | – | ﹤0.01% | 3819 |
|
|
2020
Q2 | $14K | Hold |
827
| – | – | ﹤0.01% | 3784 |
|
|
2020
Q1 | $6K | Hold |
827
| – | – | ﹤0.01% | 3741 |
|
|
2019
Q4 | $6K | Hold |
827
| – | – | ﹤0.01% | 3796 |
|
|
2019
Q3 | $9K | Hold |
827
| – | – | ﹤0.01% | 3789 |
|
|
2019
Q2 | $25K | Sell |
827
-24,726
| -97% | -$993K | ﹤0.01% | 3766 |
|
|
2019
Q1 | $1.07M | Buy |
25,553
+1,502
| +6% | +$67.9K | ﹤0.01% | 3323 |
|
|
2018
Q4 | $1.09M | Sell |
24,051
-792
| -3% | -$45.8K | ﹤0.01% | 3305 |
|
|
2018
Q3 | $2.08M | Buy |
24,843
+4,458
| +22% | +$420K | ﹤0.01% | 3230 |
|
|
2018
Q2 | $1.96M | Buy |
20,385
+9,309
| +84% | +$984K | ﹤0.01% | 3271 |
|
|
2018
Q1 | $1.17M | Buy |
11,076
+917
| +9% | +$99.6K | ﹤0.01% | 3317 |
|
|
2017
Q4 | $1.59M | Buy |
10,159
+2,431
| +31% | +$310K | ﹤0.01% | 3250 |
|
|
2017
Q3 | $1.06M | Buy |
7,728
+658
| +9% | +$111K | ﹤0.01% | 3368 |
|
|
2017
Q2 | $1.37M | Buy |
+7,070
| New | +$1.19M | ﹤0.01% | 3266 |
|
Other funds holding VRDN
BG
PBA
KCM
FFM
DTC
VA
State Street's VRDN Position: Q2 2026 in Review
State Street increased its Viridian Therapeutics (VRDN) stake by 31% in Q2 2026, buying an estimated $23.4M and bringing the position to 6,124,976 shares worth $113M. The position accounts for ﹤0.01% of the portfolio, ranked #1413.
State Street first reported a position in VRDN in Q2 2017 and has held it in 35 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.
- State Street held 6,124,976 shares of Viridian Therapeutics worth $113M as of Q2 2026.
- State Street bought 1,452,091 Viridian Therapeutics shares in Q2 2026, an estimated $23.4M.
- Viridian Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #1413 holding.
- State Street first reported a position in Viridian Therapeutics in Q2 2017 and has held it in 35 quarters since.
- 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.